Table 2.

Relative risk (RR) of CIN3+ versus ≤CIN2 by HPV type categories, overall, and stratified by age group

All agesAge <30Age ≥30
CIN3+≤CIN2RR95% CICIN3+≤CIN2RR95% CICIN3+≤CIN2RR95% CI
All women (n = 1,483)1781,3059776983534
HR-HPVa17370024.210.0–58.59550620.95.2–84.37819432.910.5–103.3
HPV-161051646.55.0–8.5611256.24.2–9.044397.75.3–11.1
HPV-1810731.00.6–1.84540.60.2–1.66191.90.9–3.9
Vaccine HR-HPV typesb1142226.14.6–8.1641665.43.6–7.950537.85.2–11.6
Non-vaccine HR-HPV typesc955951.31.0–1.7534390.90.6–1.3421562.31.5–3.4
Any α-9 HPV typed1554769.15.9–13.98934910.95.3–22.1661279.75.7–16.5
Any α-7 HPV typee341440.90.69–1.2172130.60.4–1.017731.61.0–2.5
Multiple (vs. single) HPV typesf1758810.90.7–1.1523560.90.6–1.230931.10.8–1.7
Women without multiple HPV types (n = 952)
Total968564541351443
HR-HPVa9127629.011.9–70.74317024.76.1–100.94810635.311.2–111.6
HPV-16615712.38.5–17.8323015.78.7–28.3292710.36.4–16.6
HPV-184191.80.7–4.41120.80.1–5.2373.01.1–8.1
Vaccine HR-HPV typesb657612.18.2–17.8334214.07.6–25.9323410.96.6–18.1
Nonvaccine HR-HPV typesc262001.20.8–1.8101280.70.3–1.316722.11.2–3.6
Any α-9 HPV typed8016114.88.8–24.74034919.88.0–49.0406912.86.8–24.2
Any α-7 HPV typee8721.00.5–2.012130.20.03–1.47262.21.1–4.5
  • aIncludes types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68.

  • bIncludes types 16 and 18.

  • cIncludes types 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68.

  • dIncludes types 16, 31, 33, 35, 52, 58, and 67.

  • eIncludes types 18, 39, 45, 59, 68, 70, and 85.

  • fExcludes 427 HPV-negative women.